Is Gait Speed and Sarcopenia Prognostic in Chronic Respiratory Disease?

Chronic Obstructive Pulmonary Disease and Allied Conditions Clinical Trial

Official title:

Do Gait Speed and Markers of Sarcopenia Predict Prognosis in Patients With Chronic Respiratory Disease?

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02261337
• Other study ID #: 2013LF003H
• Status: Completed
• Start date: December 2013
• Est. completion date: April 2022

Study information

• Verified date: October 2022
• Source: Royal Brompton & Harefield NHS Foundation Trust
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aims to assess usual walking speed (4-metre gait speed) and markers of sarcopenia predict mortality in patients with chronic respiratory disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 565
• Est. completion date: April 2022
• Est. primary completion date: April 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All patients with chronic respiratory disease who are able to complete the assessments.

Exclusion Criteria:

• Significant co-morbidities that would limit walking ability, exercise capacity or make exercise unsafe (e.g. unstable ischaemic heart disease, neuromuscular disease, severe hip/lower limb joint pain, peripheral vascular disease, lower limb amputation).

• Any patient whom the Chief Investigator feels it is unsafe to exercise (e.g. unstable cardiovascular disease).

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary Disease and Allied Conditions
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive
• Respiration Disorders
• Respiratory Tract Diseases
• Sarcopenia

Locations

Country	Name	City	State
United Kingdom	Harefield hospital	Harefield	Middlesex

Sponsors (2)

Lead Sponsor	Collaborator
Royal Brompton & Harefield NHS Foundation Trust	Medical Research Council

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participant deaths		1 year
Secondary	Number of participant deaths		2 years and 5 years
Secondary	Number of exacerbations as defined by a worsening of symptoms that warrant a change in medication.		1 and 2 years
Secondary	Number of hospital admissions		1 and 2 years
Secondary	Number of patients admitted to a nursing home		2 and 5 years
Secondary	Number of hospital bed days		1 and 2 years